Palo Alto, CA – According to filings with the U.S. Securities and Exchange Commission, Pheast Therapeutics is raising $76,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Amira Barkal played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Pheast Therapeutics
Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer. Activating the immune system to pheast on cancer.

To learn more about Pheast Therapeutics, visit http://www.pheast.com/

Contact:
Amira Barkal, Chief Executive Officer
650-374-2223
https://www.linkedin.com/in/amira-barkal-md-phd/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved